Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting

HUNTINGTON BEACH, California and AMSTERDAM, June 4, 2010 - Agendia, a world leader in molecular cancer diagnostics, today announced
that researchers from Agendia and leading academic centers in the U.S. and
Europe will present data from multiple studies concerning Agendia's assays
MammaPrint(R), BluePrint(TM), and ColoPrint(TM) at the American Society of
Clinical Oncology Annual Meeting, June 4 - 8, 2010, at McCormick Place in
Chicago. MammaPrint, the company's lead product, is the only FDA-cleared
breast cancer recurrence test. FDA clearance requires clinical and analytical
validation and full transparency to ensure patient safety issues are
addressed. The company anticipates launching its prognostic colon cancer test
ColoPrint in late 2010.

The study results underpin the broad predictive and prognostic
power of MammaPrint and highlight prospective and independently validated
data on ColoPrint. Visitors can meet the Agendia team in booth #18018 and
study results will be discussed at the following sessions:

    Breast Cancer

    Date: Saturday, June 5, 2010

    POSTER PRESENTATION - Abstract #10615

    Substratification of 70-gene high-risk breast cancers with a
    validated 80-gene molecular subtyping profile

    F. de Snoo, B. Chan, P. Roepman, R. A. Bender, A. Glas

    Time: 8:00 AM - 12:00 PM

    Location: S Hall A2

    Date: Saturday, June 5, 2010

    POSTER PRESENTATION - Abstract # 540

    Gene signatures as predictors of response to neoadjuvant
    chemotherapy (NCT) with docetaxel, doxorubicin, cyclophosphamide (TAC),
    or AC and nab-paclitaxel (nab-P) and carboplatin plus or minus
    trastuzumab in patients (pts) with stage II-III and inflammatory breast
    cancer (IBC)

    G. Somlo, P. H. Frankel, L. Vora, S. Lau, T. H. Luu, L.
    Kruper, J. Yim, Y. Yen, F. de Snoo, R. A. Bender

    Time: 2:00 PM - 6:00 PM

    Location: S Hall A2

    Date: Saturday, June 5, 2010

    POSTER PRESENTATION - Abstract # 561

    Evaluation of the 70-gene prognosis MammaPrint signature for
    the prediction of prognosis of breast cancer independently from
    histologic grade

    M. Knauer, E. J. Rutgers, S. Mook, J. Wesseling, L. J. van 't
    Veer

    Time: 2:00 PM - 6:00 PM

    Location: S Hall A2

    Date: Monday, June 7, 2010

    POSTER DISCUSSION - Abstract # 1520

    Effect of screening on the detection of good and poor
    prognosis breast cancers

    Y. Shieh, L. Esserman, E. J. Rutgers, M. Knauer, V. Retel, S.
    Mook, A. Glas, S. C. Linn, F. E. van Leeuwen, L. van't Veer

    Time: 2:00 PM - 6:00 PM / 5:00 PM - 6:00 PM (discussion in
    E451b)

    Location: E450b

    Colon Cancer

    Date: Monday, June 7, 2010

    POSTER PRESENTATION - Abstract # TPS199

    The PARSC trial, a prospective study for the assessment of
    recurrence risk in stage II colon cancer (CC) patients using ColoPrint

    R. Salazar, J. Marshall, L. Stork-Sloots, I. Simon, M. Lutke
    Holzik, J. Tabernero, J. J. Van Der Hoeven, F. Bibeau, R. Rosenberg

    Time: 8:00 AM - 12:00 PM

    Location: S Hall A2

    Date: Tuesday, June 8, 2010

    POSTER DISCUSSION - Abstract # 3513

    Independent validation of a prognostic genomic profile (ColoPrint) for
    stage II colon cancer (CC) patients

    R. Rosenberg, M. Maak, U. Nitsche, T. Schuster, B. Kuenzli, M. Snel, I.
    Simon, K. Janssen, H. Friess

    Time: 11:00 AM - 12:00 PM

    Location: S 406 (Vista Room)

About MammaPrint(R)

MammaPrint is the first and only breast cancer recurrence test
cleared by the U.S. Food and Drug Administration (FDA). FDA clearance under
the in vitro diagnostic multivariate index assay (IVDMIA) guidelines requires
clinical and analytical validation and reporting systems to ensure patient
safety issues are addressed. Highly accurate, MammaPrint identifies patients
with early metastasis risk - patients who are likely to develop metastases
within five years following surgery. Several authoritative studies have shown
that chemotherapy particularly reduces early metastasis risk. In planning
treatment, the MammaPrint test results provide doctors with a clear rationale
to assess the benefit of chemotherapy in addition to other clinical
information and pathology tests.

All MammaPrint tests are conducted in Agendia's CAP-accredited and CLIA
compliant service laboratories.

About Agendia

Agendia is at the forefront of the personalized medicine
revolution, striving to bring more effective, individualized treatments
within reach of patients. Building on a cutting-edge genomics platform for
tumor gene expression profiling, the company's tests help physicians more
accurately tailor cancer treatments. Agendia markets four products, with
several new genomic tests under development. In addition, Agendia
collaborates with pharmaceutical companies to develop highly effective
personalized drugs in the area of oncology. Agendia is based in Huntington
Beach, California, and in Amsterdam, The Netherlands.

MEDIA CONTACTS: Hans Herklots, Agendia, +31-20-462-1557 Office, +31-620-083-509 Mobile, hans.herklots at agendia.com; Valerie Delva, Ricochet Public Relations, +1-212-679-3300 x128 Office, +1-917-755-6194 Mobile, vdelva at ricochetpr.com